145 related articles for article (PubMed ID: 21882943)
1. Predicting in vivo safety characteristics using physiochemical properties and in vitro assays.
Greene N; Song M
Future Med Chem; 2011 Sep; 3(12):1503-11. PubMed ID: 21882943
[TBL] [Abstract][Full Text] [Related]
2. Advances in the development and use of human tissue-based techniques for drug toxicity testing.
Clotworthy M; Archibald K
Expert Opin Drug Metab Toxicol; 2013 Sep; 9(9):1155-69. PubMed ID: 23687950
[TBL] [Abstract][Full Text] [Related]
3. Investigating mitochondrial dysfunction to increase drug safety in the pharmaceutical industry.
Nadanaciva S; Will Y
Curr Drug Targets; 2011 Jun; 12(6):774-82. PubMed ID: 21275886
[TBL] [Abstract][Full Text] [Related]
4. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity.
Amacher DE
Toxicol Appl Pharmacol; 2010 May; 245(1):134-42. PubMed ID: 20219512
[TBL] [Abstract][Full Text] [Related]
5. Contribution of new technologies to characterization and prediction of adverse effects.
Rouquié D; Heneweer M; Botham J; Ketelslegers H; Markell L; Pfister T; Steiling W; Strauss V; Hennes C
Crit Rev Toxicol; 2015 Feb; 45(2):172-83. PubMed ID: 25615431
[TBL] [Abstract][Full Text] [Related]
6. High-throughput human metabolism and toxicity analysis.
Lee MY; Dordick JS
Curr Opin Biotechnol; 2006 Dec; 17(6):619-27. PubMed ID: 17046235
[TBL] [Abstract][Full Text] [Related]
7. Drug-like property concepts in pharmaceutical design.
Di L; Kerns EH; Carter GT
Curr Pharm Des; 2009; 15(19):2184-94. PubMed ID: 19601822
[TBL] [Abstract][Full Text] [Related]
8. Strategies to minimize CNS toxicity: in vitro high-throughput assays and computational modeling.
Wager TT; Liras JL; Mente S; Trapa P
Expert Opin Drug Metab Toxicol; 2012 May; 8(5):531-42. PubMed ID: 22458547
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic effects of 109 reference compounds on rat H4IIE and human HepG2 hepatocytes. III: Mechanistic assays on oxygen consumption with MitoXpress and NAD(P)H production with Alamar Blue™.
Schoonen WG; Stevenson JC; Westerink WM; Horbach GJ
Toxicol In Vitro; 2012 Apr; 26(3):511-25. PubMed ID: 22261204
[TBL] [Abstract][Full Text] [Related]
10. High-content analysis in toxicology: screening substances for human toxicity potential, elucidating subcellular mechanisms and in vivo use as translational safety biomarkers.
O'Brien PJ
Basic Clin Pharmacol Toxicol; 2014 Jul; 115(1):4-17. PubMed ID: 24641563
[TBL] [Abstract][Full Text] [Related]
11. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
Lawrence CL; Pollard CE; Hammond TG; Valentin JP
J Pharmacol Toxicol Methods; 2005; 52(1):46-59. PubMed ID: 15975832
[TBL] [Abstract][Full Text] [Related]
12. Mechanism-based selection of compounds for the development of innovative in vitro approaches to hepatotoxicity studies in the LIINTOP project.
Gómez-Lechón MJ; Tolosa L; Castell JV; Donato MT
Toxicol In Vitro; 2010 Oct; 24(7):1879-89. PubMed ID: 20656008
[TBL] [Abstract][Full Text] [Related]
13. New insights in drug-induced mitochondrial toxicity.
Nadanaciva S; Will Y
Curr Pharm Des; 2011; 17(20):2100-12. PubMed ID: 21718246
[TBL] [Abstract][Full Text] [Related]
14. Proteomics in the search for mechanisms and biomarkers of drug-induced hepatotoxicity.
Van Summeren A; Renes J; van Delft JH; Kleinjans JC; Mariman EC
Toxicol In Vitro; 2012 Apr; 26(3):373-85. PubMed ID: 22274661
[TBL] [Abstract][Full Text] [Related]
15. Zebrafish assays as early safety pharmacology screens: paradigm shift or red herring?
Redfern WS; Waldron G; Winter MJ; Butler P; Holbrook M; Wallis R; Valentin JP
J Pharmacol Toxicol Methods; 2008; 58(2):110-7. PubMed ID: 18603451
[TBL] [Abstract][Full Text] [Related]
16. ECVAM and new technologies for toxicity testing.
Bouvier d'Yvoire M; Bremer S; Casati S; Ceridono M; Coecke S; Corvi R; Eskes C; Gribaldo L; Griesinger C; Knaut H; Linge JP; Roi A; Zuang V
Adv Exp Med Biol; 2012; 745():154-80. PubMed ID: 22437818
[TBL] [Abstract][Full Text] [Related]
17. Dose metric considerations in in vitro assays to improve quantitative in vitro-in vivo dose extrapolations.
Groothuis FA; Heringa MB; Nicol B; Hermens JL; Blaauboer BJ; Kramer NI
Toxicology; 2015 Jun; 332():30-40. PubMed ID: 23978460
[TBL] [Abstract][Full Text] [Related]
18. Analysis of Pfizer compounds in EPA's ToxCast chemicals-assay space.
Shah F; Greene N
Chem Res Toxicol; 2014 Jan; 27(1):86-98. PubMed ID: 24328225
[TBL] [Abstract][Full Text] [Related]
19. Stem cell models for drug discovery and toxicology studies.
Liu W; Deng Y; Liu Y; Gong W; Deng W
J Biochem Mol Toxicol; 2013 Jan; 27(1):17-27. PubMed ID: 23293059
[TBL] [Abstract][Full Text] [Related]
20. Techniques: application of systems biology to absorption, distribution, metabolism, excretion and toxicity.
Ekins S; Nikolsky Y; Nikolskaya T
Trends Pharmacol Sci; 2005 Apr; 26(4):202-9. PubMed ID: 15808345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
